Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Proprotein subtilisin kexin type 9 (PCSK9) and lipoprotein (a) [Lp(a)] levels are causative risk factors for coronary heart disease.
|
29103916 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Elevated plasma concentrations of lipoprotein(a) [Lp(a)] are an independent, and possibly causal, risk factor for atherothrombotic diseases including coronary heart disease.
|
30316749 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Moreover, BAX methylation was associated with smoking and lipoprotein A (Lp(a)) for individuals aged over 70 (CHD: smoking P = .012, Lp(a) P = .001; non-CHD: smoking P = .051, Lp(a) P = .004).
|
30681575 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The relative expression of EGR1 in plasma of patients with CHD was negatively correlated with lipoprotein a [Lp(a)] and high sensitive C-reactive protein (hs-CRP) (r=-0.394 and -0.524, P<0.05), and the relative expression of CD69 in peripheral blood was positively correlated with [Lp(a)] and hs-CRP (r=0.352 and 0.402, P<0.05).
|
30783476 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) and coronary artery disease in Chinese postmenopausal female patients: a large cross-sectional cohort study.
|
31315919 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Prediabetes or Diabetes.
|
31076417 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Association of lipoprotein(a) and coronary artery disease in 1003 patients with stage 3-5 chronic kidney disease undergoing coronary angiography.
|
30585793 |
2019 |
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Levels of Lipoprotein (a) in patients with coronary artery disease with and without inflammatory rheumatic disease: a cross-sectional study.
|
31079089 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Genetic LPA score, plasma Lp(a) concentrations, and observations of statin therapies on CHD outcomes.
|
31017618 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, we investigated whether selection bias may explain a recently reported finding that lipoprotein(a) is not a causal risk factor for cardiovascular mortality in individuals with previous coronary heart disease.
|
30325422 |
2019 |
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A genome-wide association study on lipoprotein (a) levels and coronary artery disease severity in a Chinese population.
|
31186284 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) and other ASCVD risk factors were measured at baseline (1996-1998) in the biracial Atherosclerosis Risk in Communities study; participants without prevalent ASCVD (coronary heart disease or stroke) were monitored ∼15 years for incident ASCVD events.
|
30685442 |
2019 |
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Prognostic value of lipoprotein (a) level in patients with coronary artery disease: a meta-analysis.
|
31286992 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.
|
30447089 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Impact of Lipoprotein (a) Levels on Long-Term Outcomes in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction.
|
30918220 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis.
|
30482443 |
2019 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Blood samples were collected before angiography in 32 subjects (mean age 56 ± 8 years) with stable coronary heart disease (CHD) and elevated lipoprotein(a) (Lp(a), 94 ± 35 mg/dL).
|
30934954 |
2019 |
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
<b>Objective:</b> The study tested whether cardiovascular corresponding LPA risk genotypes improve pre-eclampsia and coronary heart disease (CHD) risk prediction beyond conventional risk factors.
|
31113255 |
2019 |
Coronary heart disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
However, clinical impacts of lipoprotein(a) levels on adverse vascular events in patients with established coronary artery disease who are undergoing statin treatment have not been fully elucidated.
|
31577620 |
2019 |
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.
|
29926099 |
2018 |
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] is an enigmatic lipoprotein which has been identified as a causal risk factor for coronary heart disease and calcific aortic valve disease.
|
29990619 |
2018 |
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Elevated plasma lipoprotein(a) levels were associated with increased risk of cardiovascular events in Chinese patients with stable coronary artery disease.
|
29769559 |
2018 |
Coronary heart disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In these patients, low adiponectin and high lipoprotein(a) levels are found which are known to be associated with endothelial dysfunction, atherosclerosis and coronary artery disease.
|
27007665 |
2018 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque.
|
29960898 |
2018 |
Coronary heart disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The analysis was designed to explore the combined effects of LDL-cholesterol and lipoprotein(a) (Lp(a)) in predicting incident coronary heart disease (CHD) in senior citizens without prior CHD.
|
28583815 |
2018 |